期刊文献+

肿瘤抗原冲击的DC联合CIK细胞治疗复发性多发性骨髓瘤的疗效 被引量:2

Clinical study of combined immunotherapy with tumor antigen-pulsed dendritic cells and cytokine-induced killer cells for relapsed multiple myeloma
下载PDF
导出
摘要 目的:观察树突状细胞(dendritic cells,DC)联合细胞因子诱导的杀伤(cytokine-induced killer,CIK)细胞治疗复发性多发性骨髓瘤(multiple myeloma,MM)的疗效以及安全性。方法:采集2005年3月至2014年10月江苏省中医院血液科收治的22例复发性MM患者的骨髓瘤细胞以及外周血单个核细胞,体外培养扩增自体DC-CIK细胞,然后回输治疗,对比治疗前后患者免疫指标及临床治疗效果。结果:DC联合CIK细胞治疗复发性MM总体疗效为,完全缓解(CR)2例,接近完全缓解(n CR)5例,部分缓解(PR)7例,轻微治疗反应(MR)3例,疾病进展(PD)5例,总体反应率(CR+n CR+PR)为63.64%(14/22)。DC-CIK细胞治疗后患者外周血T细胞亚群比例较治疗前无明显变化,差异无统计学意义(P>0.05);NK细胞百分率较治疗前明显上升[(22.26±9.67)%vs(12.61±8.78)%],差异有统计学意义(P<0.01);LDH含量[(166±41)%vs(112±21)%]和β2-MG含量[(5.11±2.33)%vs(2.65±1.61)%]较治疗前均有明显下降,差异有统计学意义(P<0.01)。结论:DC-CIK细胞联合治疗复发性MM具有较好的临床疗效,是一种安全、有效的治疗方法,有望进一步在骨髓瘤及其他B细胞肿瘤的临床治疗中得到应用。 Objective: To evaluate the clinical efficacy and safety of combined immunotherapy with dendritic cells( DCs) and cytokine-induced killer( CIK) cells in the treatment of relapsed multiple myeloma( MM). Methods: Bone marrow myeloma cells and peripheral blood mononuclear cells were collected from 22 cases of relapsed MM. The autologous DCs and CIK cells were amplified in vitro and used for reinfusion treatment. The clinical responses and immune parameters before and after the treatment were compared. Results: Among the 22 patients,2 had CR in response to the combined therapy,5 had n CR,7 had PR,3 had MR,and 5 had PD. Thus,the overall response rate( CR + n CR + PR) was63. 64%( 14 /22). After the treatment,the percentages of T cells subsets in peripheral blood did not change significantly( P > 0. 05),whereas the percentage of NK cells increased significantly( [22. 26 ± 9. 67]% vs [12. 61 ± 8. 78]%,P <0. 01). Furthermore,the blood levels of LDH( [166 ± 41]% vs [112 ± 21]%) and β2-MG( [5. 11 ± 2. 33]% vs[2. 65 ± 1. 61]%) were significantly improved following the immunotherapy( P < 0. 01). Conclusion: The combined therapy with DC and CIK cells are safe and effective for relapsed MM. The treatment should be further tried in more patients with multiple myeloma and perhaps patients with B cell malignancies.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2015年第6期785-789,共5页 Chinese Journal of Cancer Biotherapy
基金 江苏省六大人才高峰项目资助(No.2010-WS-012) 江苏省卫生拔尖人才项目资助(No.2014-333-063)~~
关键词 多发性骨髓瘤 树突状细胞 细胞因子诱导的杀伤细胞 免疫治疗 multiple myeloma(MM) dendritic cells(DCs) cytokine-induced killer(CIK) cells immunotherapy
  • 相关文献

参考文献13

  • 1Palucka K,Ueno H,Banchereau J.Recent developments incancer vaccines. J Immunol . 2011
  • 2Dr C. D. L.Reid.??Dendritic cells and immunotherapy for malignant disease(J)British Journal of Haematology . 2001 (4)
  • 3Derry Ridgway.??The First 1000 Dendritic Cell Vaccinees(J)Cancer Investigation . 2003 (6)
  • 4Thanh-Nhan Nguyen-Pham,Chang-Min Im,Truc-Anh Thi Nguyen,Mi-Seon Lim,Cheol Yi Hong,Mi-Hyun Kim,Hyun Ju Lee,Youn-Kyung Lee,Duck Cho,Jae-Sook Ahn,Deok-Hwan Yang,Yeo-Kyeoung Kim,Ik-Joo Chung,Hyeoung-Joon Kim,Je-Jung Lee.??Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma(J)Leukemia Research . 2011 (9)
  • 5S. Hong,H. Li,J. Qian,J. Yang,Y. Lu,Q. Yi.??Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti‐tumour immunity(J)Clinical & Experimental Immunology . 2012 (2)
  • 6S. Vincent Rajkumar.??Multiple myeloma: 2014 Update on diagnosis, risk‐stratification, and management(J)Am. J. Hematol. . 2014 (10)
  • 7朱学军,曹雪涛,于益芝,陈国友,万涛,马施华,唐华,章卫平.人外周血树突状细胞的体外扩增及鉴定[J].中国肿瘤生物治疗杂志,1997,4(4):302-306. 被引量:91
  • 8朱学军,李晓惠,夏雯,张文曦,陈健一.人外周血树突状细胞体外稳定、高效培养的新方法[J].中国肿瘤生物治疗杂志,2007,14(6):575-577. 被引量:5
  • 9朱学军.树突状细胞疫苗治疗恶性肿瘤:挑战与希望[J].内科理论与实践,2008,3(2):114-117. 被引量:6
  • 10朱学军,何龙,孙雪梅.树突状细胞疫苗治疗多发性骨髓瘤的研究进展[J].中国实验血液学杂志,2009,17(3):821-825. 被引量:4

二级参考文献39

  • 1Wang S,Hong S,Wezeman M,et al.Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.Front Biosci,2007, 12:3566-3575
  • 2Van de-Velde AL,Berneman ZN,Van Tendeloo VF.Immunotherapy of hematological malignancies using dendritic cells.Bull Cancer,2008, 95:320-326
  • 3Hundemer M,Schmidt S,Condomines M,et al.Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.Exp Hematol,2006,34:486-496
  • 4Rew SB,Peggs K,Sanjuan I,et al.Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.Clin Cancer Res,2005 , 11:3377-3384
  • 5Qian J,Xie J,Hong S,et al.Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.Blood,2007, 110:1587-1594
  • 6Dadabayev AR,Wang Z,Zhang Y,et al.Cancer immunotherapy targeting Sp17:when should the laboratory findings be translated to the clinics? Am J Hematol,2005 , 80:6-11
  • 7Lee JJ,Choi BH,Kang HK,et al.Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates.Leuk Lymphoma,2007 , 48:2022-2031
  • 8Hayashi T,Hideshima T,Akiyama M,et al.Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.Blood,2003 ,102:1435-1442
  • 9Vasir B,Borges V,Wu Z,et al.Fusion of dendritic eels with multiple myeloma cells results in maturation and enhanced antigen presentation.Br J Haematol,2005 , 129:687-700
  • 10Xia D,Chan T,Xiang J.Dendritic cell/myeloma hybrid vaccine.Methods Mol Med,2005, 113:225 -233

共引文献100

同被引文献24

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部